finance.yahoo.com ·
xeris biopharma q1 earnings call 080705564
The full article is on the original publisher site. This page only shows the headline and a very short excerpt.
AI insight
AI-generatedXeris Biopharma's strong Q1 results and raised guidance are driven by RECORLEV's commercial expansion and record patient starts. The impact is company-specific, with no direct commodity or supply chain scarcity. The primary commercial mechanism is revenue growth from increased product demand, improving gross margins and cash flow for Xeris.
Signals our AI researcher identified
Extracted by our AI model from this article and related public sources — not direct quotes from the publisher.
- Xeris Biopharma Q1 2026 total revenue $83.1M, +38% YoY
- Net product revenue $82.5M, +43% YoY
- RECORLEV revenue nearly doubled to ~$50M
- Full-year revenue guidance raised to $380M-$390M
- Phase 3 trial for XP-8121 planned later in 2026
RECORLEV expected to drive Xeris Biopharma shares up 2% in 48h following strong Q1 results and raised guidance.
Sign in to see all sector verdicts, full thesis and counter-argument debate.